It seems that tumor patients developing proteinuria after TKI treatment cannot benefit from HGF, but this may partly explain the predictive role of TKI-induced proteinuria on anticancer efficacy [133,134]—that is, patients with proteinuria may have low levels of HGF. The gene discussed is HGF; the disease is neoplasm.